


**BEST AVAILABLE COPY**



## **Europäisches Patentamt**

## **European Patent Office**

## **Office européen des brevets**



(11) Publication number : 0 657 463 A1

12

# **EUROPEAN PATENT APPLICATION**

(21) Application number : 94309061.3

(51) Int. Cl.<sup>6</sup>: C07F 9/6506, A61K 9/127,  
C08G 65/32, A61K 47/48,  
A61K 47/30

22 Date of filing : 06-12-94

(30) Priority : 06.12.93 JP 305611/93  
06.12.93 JP 305612/93  
16.12.93 JP 317026/93  
16.12.93 JP 317027/93  
17.06.94 JP 135954/94

(43) Date of publication of application :  
14.06.95 Bulletin 95/24

⑧4 Designated Contracting States :  
**CH DE FR GB IT LI NL SE**

⑦1 Applicant : NOF CORPORATION  
20-3, Ebisu 4-chome,  
Shibuya-ku  
Tokyo (JP)

(72) Inventor : Miyazaki, Tsuyoshi  
2-15-5, Umezono  
Tsukuba-shi, Ibaraki (JP)  
Inventor : Maruyama, Kazuo  
3-1-50, Nihonmatsu  
Sagamihara-shi, Kanagawa (JP)  
Inventor : Iwatsuru, Motoharu  
4-43, Daimachi  
Hachioji-shi, Tokyo (JP)

**Inventor : Sanchika, Kouzoh  
2-3-9, Fujisaki,  
Kawasaki-ku  
Kawasaki-shi, Kanagawa (JP)**

**Inventor : Nishida, Mitsuhiro  
2-53, Mukonoso Nishi  
Amagasaki-shi, Hyogo (JP)**

**Inventor : Yasukohchi, Tohru  
2-3-10, Fujisaki,  
Kawasaki-Ku  
Kawasaki-Shi, Kanagawa (JP)**

**Inventor : Kitano, Shigeru  
B-207, TT-Suncity, 2-17-14, Kasuga  
Tsukuba-Shi, Ibaraki (JP)**


**Inventor : Suginaka, Akinori  
2-4-10, Murota  
Chigasaki-Shi, Kanagawa (JP)**

**Inventor : Kadoma, Yoshihito  
3-2-6, Oguradai,  
Kita-ku  
Kobe-Shi, Hyogo (JP)**


**(74) Representative : Perry, Robert Edward  
GILL JENNINGS & EVERY  
Broadgate House  
7 Eldon Street  
London EC2M 7LH (GB)**

**54 Phospholipid derivative and vesicle comprising the same.**

57 A novel and useful reactive phospholipid derivative is represented by the following general formula (1)



in which  $R^1C(=O)$  and  $R^2C(=O)$  are independently selected from aliphatic acyl groups,  $R^3$  denotes a hydrogen atom or a methyl group, OA represents an oxyalkylene group having 2 - 4 carbon atoms,  $m$  indicates the average number of moles of added oxyalkylene groups and is 1 - 1000,  $p$  is O or 1, X represents



with  $q$  and  $r$  being each an integer of 0 to 4 or 1 to 4, respectively, and  $M$  denotes hydrogen atom or an

EP 0 657 463 A1

alkali metal atom. The novel derivative is used to form vesicles and to attach functional substances to those vesicles.

## FIELD OF THE INVENTION

The present invention relates to novel and useful phospholipid derivatives, and to vesicles comprising or derived from the same, including vesicles having a functional group fixed thereonto. More specifically, the present invention relates to phospholipid derivatives to be used, for example, as a drug carrier for medicaments etc., testing drugs, diagnostic drugs, sensors, fixed catalysts, bioreactors, bioelectronics elements and a substitute for microcapsules, as well as for the production of various functional liposomes and fatty emulsions.

## BACKGROUND OF THE INVENTION

Liposome is a lipid vesicle composed of a phospholipid bilayer and has been attempted to find its application in various fields. Attention has been paid, in particular, to the application to drug carrier and sensors for diagnosis and detection, where large problems have been encountered in providing the liposome with a specific function by fixing a special functional substance onto or into the liposome and in maintaining the concentration of such liposome cells in the blood.

Heretofore, there have been reported as for the fixation of functional substances onto or into a liposome, for example, a method in which fragments of an antibody are bound to an aminoethyl carbamoyl-methyl group substituted on the polysaccharide on the surface of a liposome covered with a pullulan derivative via  $\gamma$ -maleimidobutyloxysuccinimidyl [ See "Biochem. Biophys. Acta.", 898, 323 (1987) ] and a method in which an antibody is fixed onto a liposome in such a manner that a glycolipid is added preliminarily to the ingredients for forming the liposome membrane and, after the liposome has been formed, a periodate oxidation is carried out and the thereby formed aldehyde group is reacted with the antibody [See "J. Biol. Chem.", 255, 10509 (1980)].

These prior arts include, however, a problem that a multistep chemical reaction on the liposome membrane has to be incorporated after the liposome has been formed and, thus, the amount of the contemplated functional substance introduced is limited to a lower value, with simultaneous high possibility of contamination by the by-products and impurities, bringing about a large probability of damage of the liposome membrane.

On the other hand, it has been pointed out that no sufficient effect is achieved by the use of liposome, since a large part of the liposome is caught by organs in the reticuloendothelial system, such as liver, spleen etc., upon administration of the liposome product [Cancer Res., 43, 5328 (1983)]. In order to solve problems by the above-mentioned liposome capture in the organs of reticuloendothelial system and by the low stability of liposome itself, such as the tendency to collapse and coagulation, attempt has been made to introduce polyethylene glycol chains into the surface layer of liposome [See, for example, WO 90/4384, Japanese Patent Application Kokai No. 249717/1989 and FEBS Letters, 268, 235 (1990) ]. Also, it has been made clear that a liposome modified by polyethylene glycol can afford to maintain the liposome concentration in blood for long period of time [Biochem. Biophys. Acta, 1066, 29 - 36 (1991)] .

However, the liposome having introduced therein polyethylene glycol chains does not react with functional substances, so that these functional substances can not be fixed on the liposome surface.

In European Patent Publication No. 526700, it is taught that an antibody-bound liposome containing a drug in which the problem of drug capturing in organs of reticuloendothelial system is improved can be obtained by reacting a maleimide group-containing liposome first with a protein provided with thiol groups (thiolated protein) and reacting, then, the remaining maleimide groups with a compound having a moiety of a polyalkylene glycol having thiol groups (thiolated polyalkylene glycol).

This liposome has, however, a defect that the expected effect is not attained sufficiently, since the antibody is hidden behind the polyalkylene glycol layer and the reaction of the antibody with the target site is obstructed.

In WO 91/16040, a liposome preparation is disclosed, which comprises an anionic group-containing polyethylene glycol derivative, such as an  $\alpha$ -stearyl- $\omega$ -propionic acid-polyoxyethylene. However, this polyoxyethylene derivative tends to separate off easily from the liposome membrane, since the hydrophobic moiety thereof consists of a monoalkyl group, so that a liposome containing such polyoxyethylene derivative as the membrane-forming component is inferior in the long term stability.

## SUMMARY OF THE INVENTION

An object of the present invention is to provide a novel and useful phospholipid derivative which permits to fix various functional substances easily and efficiently by a covalent bond onto the top ends of (poly)oxyalkylene chains.

Another object of the present invention is to solve the above-mentioned problems incidental to the prior techniques and to provide a reactive vesicle-forming agent which may be composed of a vesicle, such as a liposome, having provided with (poly)oxyalkylene chains and which permit to fix various functional substances


onto the top ends of the (poly)oxyalkylene chains easily and efficiently by a covalent bond and to increase the charged amount of the functional substance.

Another object of the present invention is to provide a reactive vesicle in which (poly)oxyalkylene chains having provided at the top end with a reactive oxycarbonylimidazole group are introduced and which permits to fix various functional substances easily and efficiently in a larger amount by a covalent bond onto the top ends of the (poly)oxyalkylene chains and which is superior in the long term storage stability.

Another object of the present invention is to provide a functional substance-fixed vesicle which comprises a vesicle having combined on its surface, under intermediation by a spacer consisting of a (poly)oxyalkylene chain, a functional substance and which is superior in the long term storage stability and is capable of maintaining its concentration in blood for long period of time, while revealing sufficient function of the functional substance fixed thereon.

A further object of the present invention is to provide a drug delivery vesicle made from the reactive vesicle or made of the functional substance-fixed vesicle, especially the one having a target-directing property.

The present invention provides, thus, a phospholipid derivative represented by the following general formula (1) and a reactive vesicle-forming agent composed of such phospholipid derivative:



in which

### **R<sup>1</sup>C(=O) and R<sup>2</sup>C(=O)**

represent each an aliphatic acyl group having 3 - 30 carbon atoms and may be identical or different from each other.

R<sup>3</sup>

.30 OA

8



denotes hydrogen atom or methyl group; represents an oxalkylene group of 2-4

represents an oxyalkylene group of 2 - 4 carbon atoms, indicates the average addition mole number of adduct.

35 p

x


represents the group



wherein q is an integer of 0 to 4 and r is an integer of 1 to 4 and denotes hydrogen atom or an alkali metal atom.

According to the present invention, there is provided a reactive vesicle which comprises a reactive phospholipid derivative represented by the above general formula (1).

According to the present invention, there is provided also a functional substance-fixed vesicle comprising, as a vesicle-forming component, one or more phospholipid derivatives represented by the general formula (2):



10 in which

$\text{R}^1\text{C}(=\text{O})$ ,  $\text{R}^2\text{C}(=\text{O})$ ,  $\text{R}^3$ ,  $\text{OA}$ ,  $n$ ,  $p$ ,  $\text{X}$ ,  $q$ ,  $r$  and  $\text{M}$  are as defined above, and  $\text{Y}$  denotes the residue of a functional substance.

According to the present invention, there is provided further a drug delivery system, which comprises the reactive vesicle or the functional substance-fixed vesicle mentioned above.

15

#### DETAILED DESCRIPTION OF THE INVENTION

In the context of the present application, the term "(poly)oxyalkylene" does mean oxyalkylene or polyoxalkylene. Similarly, the term "(poly)alkylene" means alkylene or polyalkylene.

20

The "vesicle" as used in the present invention means a cellular particle having a structure in which the hydrophilic groups of the phospholipid derivative represented by the general formula (1) or (2) and of other vesicle-forming components are oriented towards the aqueous phase from the surface membrane. Concrete examples therefor include a closed vesicle composed of a liposome, a fatty emulsion in which a mixture of vegetable oil and phospholipid is emulsified and micells.

25

The acyl groups of fatty acids represented by  $\text{R}^1\text{C}(=\text{O})$  and  $\text{R}^2\text{C}(=\text{O})$  in the general formula (1) or (2) are those having 3 - 30, preferably 8 - 20 carbon atoms inclusive of the carbonyl carbon. Concrete examples of such acyl groups include those of saturated fatty acids, such as propionic acid, butyric acid, caproic acid, caprylic acid, pelargonic acid, capric acid, undecanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachic acid, behenic acid, lignoceric acid, solanic acid, montanic acid, melissic acid, 2-ethyl hexanoic acid; those of unsaturated fatty acids, such as oleic acid, linoleic acid, linolenic acid, erucic acid and 2,4-octadecadienoic acid; those of branched fatty acids, such as isostearic acid; and those of fatty acids having hydroxyl group in the alkyl moiety, such as ricinoleic acid and 12-hydroxy stearic acid.

30

In the reactive vesicle, the functional substance-fixed vesicle and the drug transporting vesicle according to the present invention, the acyl groups of fatty acids represented by  $\text{R}^1\text{C}(=\text{O})$  and  $\text{R}^2\text{C}(=\text{O})$  in the general formula (1) or (2) may preferably be those of myristic acid, palmitic acid, stearic acid, oleic acid and 2,4-octadecadienoic acid, in particular, palmitic acid, stearic acid and oleic acid, since these can produce a stable liposome or fatty emulsion. The groups  $\text{R}^1\text{C}(=\text{O})$  and  $\text{R}^2\text{C}(=\text{O})$  may either be identical with or different from each other.

35

The oxyalkylene group represented by  $\text{OA}$  in the general formula (1) or (2) has 2 - 4 carbon atoms, namely, for example, oxyethylene, oxypropylene, oxytrimethylene, oxy-1-ethyl-ethylene, oxy-1,2-dimethyl-ethylene and oxytetramethylene. These oxyalkylene groups are derived from addition of alkylene oxides, such as ethylene oxide, propylene oxide, oxetane, 1-butene oxide, 2-butene oxide and tetrahydrofuran.

40

The number  $n$  in the general formula (1) or (2) may be a positive number of 1 - 1,000, preferably, 10 - 300 and most preferably 20 - 120.

45

In case  $n$  is 2 or higher, the oxyalkylene groups in the phospholipid derivative may either be identical with or different from each other. If they are different, they may be in a form of random addition or block addition.

50


For providing the phospholipid derivative with a hydrophilicity, the group  $\text{OA}$  may preferably be derived from a sole polyaddition of ethylene oxide, wherein  $n$  may preferably be 10 or higher. In case the polyoxyalkylene group is derived from polyaddition of different alkylene oxides, it may preferably be composed of 20 mole % or more, preferably 50 mole % or more of oxyethylene groups. For providing the (poly)oxyalkylene chain with an oleophilicity, the number of moles of added alkylene oxide other than ethylene oxide is increased.

In the general formula (1) or (2),  $p$  denotes 0 or 1 and, if  $p = 1$ ,  $\text{X}$  is selected from the bivalent organic groups mentioned above.

55

$\text{R}^3$  of the general formula (1) represents a hydrogen atom or a methyl group.  $\text{M}$  of the general formula (1) or (2) denotes hydrogen atom or an alkali metal atom, such as sodium or potassium.

In case  $p$  of the general formula (1) is 1, the reactive phospholipid derivative is represented by the general formula (1-1) or (1-2) given below and, if  $p$  is zero, it is represented by the general formula (1-3) also given below:



30

In these general formulae, the symbols same with those of general formula (1) have the same meanings.


The reactive phospholipid derivative of general formula (1-1), namely that of general formula (1) with  $p = 1$ , can be produced easily by, for example, reacting a (poly)oxyalkylene derivative having a carboxyl group at its one end and a hydroxyl group at the other end with *N,N'*-dicyclohexylcarbodiimide (DCC) to form an active derivative and subjecting this derivative then to a reaction with a phosphatidylethanolamine, whereupon the resulting product is reacted with *N,N'*-carbonyldiimidazole (CDI). The production procedures using an  $\alpha$ -hydro- $\omega$ -carboxy polyoxyethylene [ $\alpha$ -(2-carboxy)ethyl- $\omega$ -hydroxy polyoxyethylene] for the (poly)oxyalkylene derivative and dipalmitoyl-glycero-phosphoethanolamine (DPPEA) for the phosphatidylethanolamine is given in the following reaction scheme (3a):

40

45

50

55




5

↓ DCC

10


↓ DPPEA



15

↓ CDI

20



25

....(3a)

30

The phospholipid derivatives can also be produced easily in an alternative way, for example, by preparing an active product of the (poly)oxyalkylene derivative by converting its carboxyl group into acid chloride group using, for example, thionyl chloride or isobutyl chloroformate, or into an active ester using, for example, succinimide or N,N'-carbonyldiimidazole, and reacting this active product with a phosphatidylethanolamine, whereupon the resulting product is reacted with CDI. By this, phospholipid derivatives of general formula (1-1) with q = 1 to 4 are obtained.

The phospholipid derivatives can be produced easily in a further alternative way by reacting a phosphatidylethanolamine with a (poly)oxyalkylene derivative having at its both ends each an oxycarbonyl imidazole group in a mixing mole proportion of 1:1 to 1:1,000. By this, phospholipid derivatives of the general formula (1-1) with q = 0 are obtained.

The above reactions can be realized without solvent or in an aqueous medium, such as water, saline, a phosphate buffer, a tris buffer, a carbonate buffer or a borate buffer, or further in an organic solvent, such as toluene, acetonitrile, methanol, ethanol, 1,4-dioxane, tetrahydrofuran, chloroform, methylene chloride or diethyl ether, in the atmospheric air or under an inert atmosphere of argon, helium or carbon dioxide gas at a temperature of -40 to +120 °C preferably 0 to 60°C, for 10 minutes to 240 hours, preferably 1 - 48 hours, preferably with agitation.

The phospholipid derivatives represented by the general formula (1) with p = 1, namely, those of the general formula (1-2), can be produced easily, for example, in such a manner, that an α-hydro-ω-hydroxy polyoxyethylene is reacted with a dicarboxylic acid anhydride, such as succinic anhydride (SAN), in a mole proportion of 1:1 to 1:0.01, followed by purification by, for example, treatment on a column, to obtain a polyoxyethylene derivative having a carboxyl group at its one end and a hydroxyl group at the other end, whereupon this polyoxyethylene derivative is reacted with a phosphatidylethanolamine in a similar manner as in the production of the phospholipid derivative of the general formula (1-1). The reaction sequence for this is shown in the following reaction scheme (3b), in which M and n have the same meanings as those given previously.

55


5



SAN

10

Column Purification





15

DCC

20


DPPEA




25

CDI

30



35



.....(3b)

40 The reactive phospholipid derivatives represented by the general formula (1) with  $p = 0$ , namely those of the general formula (1-3), can be produced easily, for example, by a two-step reaction in the following way:

In the first step reaction, a phosphatidyl (poly)alkylene glycol is synthesized by reacting a phospholipid with an  $\alpha$ -hydro- $\omega$ -hydroxy (poly)oxyalkylene in the presence of an enzyme phospholipase D (PLase-D). As the phospholipase D to be used here, either a commercial product or an extracted and purified product obtained by the method described in J. Biol. Chem., 242, 477-484 (1967) can be employed. As the phospholipid, for example, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol or phosphatidic acid, can be employed. Phospholipase D may preferably be used in an amount of, though not limited specifically, 100 to 500 units per gram of the phospholipid. The mixing proportion of the phospholipid and the  $\alpha$ -hydro- $\omega$ -hydroxy (poly)oxyalkylene may preferably be 5 - 100 moles of the  $\alpha$ -hydro- $\omega$ -hydroxy (poly)oxyalkylene per mole of the phospholipid.

55 The reaction may be carried out preferably in an aqueous medium, such as an acetate buffer or a carbonate buffer, or in a mixed medium composed of such an aqueous medium and an organic solvent, such as chloroform, benzene, toluene, tetrahydrofuran or acetonitrile. The reaction may be effected at a temperature of 0 - 80 °C, preferably 30 - 40°C, for 10 minutes - 170 hours, preferably for 30 minutes to 24 hours.

The phosphatidyl (poly)alkylene glycol product obtained in this manner may be used for the second step reaction as such or after isolation and purification by, for example, re-precipitation, treatment on a column, treatment by adsorption, ion-exchange, gel filtration, ultrafiltration or dialysis.

In the second step reaction, the contemplated reactive phospholipid derivative is synthesized by reacting


the phosphatidyl (poly)alkylene glycol with N,N'-carbonyldiimidazole or a substituted product thereof. While there is no special limitation in the mixing proportion of the starting reactants, it is preferable to use 0.1 - 100 moles, preferably 1 - 10 moles of N,N'-carbonyldiimidazole or its substitution product per mole of the phosphatidyl (poly)alkylene glycol.

5 The reaction may preferably be carried out in an organic solvent, such as chloroform, benzene, toluene, tetrahydrofuran or acetonitrile. The reaction temperature may preferably be in the range from -100°C to +100 °C, preferably from 0 °C to 40°C, and the reaction duration may be in the range from 1 minute to 48 hours, preferably from 10 minutes to 6 hours.


10 The reaction course using an  $\alpha$ -hydro- $\omega$ -hydroxy polyoxyethylene as the  $\alpha$ -hydro- $\omega$ -hydroxy (poly)oxyalkylene is given in the following reaction scheme (4), in which R<sup>1</sup>C(=O), R<sup>2</sup>C(=O), M and n are the same with those of the general formulae given above and PL-PEG represents phosphatidyl (poly)ethylene glycol:

15

### Phospholipid




20



I CDI

30



.... (4)

40

After the reactive phospholipid derivative represented by the general formula (1) has been produced as above, it can be used, for example, as a component for forming a vesicle, in the form of the reaction mixture as such or after it is isolated and purified from the reaction mixture by distillation, recrystallization, re-precipitation, treatment by adsorption, treatment on a column, gel filtration, ultrafiltration, dialysis, ion-exchange or thin layer chromatography.

45 The reactive vesicle according to the present invention comprises, as the vesicle-forming component, the reactive phospholipid derivative represented by the general formula (1). Since the reactive phospholipid derivative to be served as the vesicle-forming component includes an oxy carbonylimidazole group which has a high reactivity to various functional substances having functional group(s) of amino, hydroxyl, thiol and so on, especially primary amino group, the vesicle containing such reactive phospholipid derivative will react easily with such functional substances. The reactive phospholipid derivative represented by the general formula (1) may be incorporated either solely or in combination of two or more of them. As the vesicle-forming component, other ones such as those which are capable of forming vesicle may be employed in addition to that represented by the general formula (1).

55 As other vesicle-forming component, for example, other phospholipids, such as soybean lecithin and yolk lecithin, cholesterol, Intralipid (Trademark, Otsuka Pharmaceutical Co., Ltd.), soybean oil and safflower oil, may be employed. The reactive vesicle according to the present invention can be produced using these components by known methods.

Various functional substances can be introduced into the reactive vesicle obtained by using the reactive phospholipid derivative according to the present invention, by a covalent bond by making use of the oxycarbonylimidazole group or its substituted group in the compound represented by the general formula (1) as a functional group.

5 The functional substance-fixed vesicle according to the present invention contains the phospholipid derivative represented by the general formula (2) as a vesicle-forming component. Such functional substance-fixed vesicle can be obtained by reacting the reactive vesicle with a functional substance having functional group(s) capable of reacting with oxycarbonylimidazole group or a substituted group thereof.

10 The drug delivery vesicle according to the present invention comprises the reactive vesicle or the functional substance-fixed vesicle containing enclosed therein a drug, such as medicament. In particular, if the functional substance fixed to the drug delivery vesicle composed of the functional substance-fixed vesicle is an antigen or an antibody, the resulting drug delivery vesicle possesses a target-directing property due to the action of the so-fixed antigen or antibody.

15 Below, the reactive vesicle, the functional substance-fixed vesicle and the drug delivery vesicle according to the present invention will be described in detail for each of their forms of liposome, fatty emulsion and micell.

20 A reactive liposome as a representative reactive vesicle comprises the reactive phospholipid derivative represented by the general formula (1) as a membrane-forming component (vesicle-forming component). The content of the reactive phospholipid derivative represented by the general formula (1) may preferably be in the range of 0.01 - 50 mole %, preferably 0.5 - 30 mole %, based on the total moles of the reactive phospholipid derivative represented by the general formula (1) and other membrane-forming components. If this content is less than 0.01 mole %, the expected effect will be low and, if it exceeds over 50 mole %, the stability of the liposome becomes decreased and such a content is not chosen in general. The reactive phospholipid derivatives represented by the general formula (1) may be used each solely or in combination of two or more of them.

25 As other membrane-forming components to be used in combination with the reactive phospholipid derivative represented by the general formula (1), those which have hitherto found their application for the membrane-forming component of liposomes can be employed without limitation. Concrete examples therefor include phospholipids and polymerizable phospholipids having unsaturated group(s) in the acyl group of fatty acids, such as diphosphatidylglycerol, cardiolipin, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, soybean lecithin, yolk lecithin, phosphatidylcholine and phosphatidylglycerol; glycolipids, such as 30 sulfoxyribosyldiglyceride, digalactosyldiglyceride and lactosyldiglyceride; nonpolar lipids, such as cholesterol; and others, such as nonionic surfactants, phosphatidyl polyethylene glycol and reaction products of phosphatidylethanolamine with  $\alpha$ -hydro- $\omega$ -hydroxy polyoxyethylene, such as those described in Biochem. Biophys. Acta, 1066, 29 - 36 (1991), as well as mixtures of them.

35 Reactive liposomes according to the present invention can be produced by various methods, for example, by dissolving a reactive phospholipid derivative represented by the general formula (1) and, if necessary, other membrane-forming components, such as other phospholipids such as lecithin, or cholesterol, in an adequate medium, such as an organic solvent, and processing the resulting solution into a liposome by a known technique, such as extrusion method, vortex mixer method, ultrasonication method, surfactant-removal method, reversed phase evaporation, ethanol introducing method, prevesicle method, french-press method, W/O/W-emulsion method, annealing method or freeze thawing method. By choosing an appropriate technique among 40 them, reactive liposomes having various sizes and morphologies can be produced.

45 The reactive liposome obtained as above has an oxycarbonylimidazole group or its substituted group suspending from the both side surfaces of the resulting liposome membrane under intermediation by a spacer consisting of a (poly)oxyalkylene chain, so that it can afford to fix various functional substances having functional group(s), such as amino, hydroxyl, thiol and the like, in particular, primary amino group, easily and efficiently onto the bimolecular membrane of the liposome through a chemical bond, such as urethane bond, carbonate bond, thiocarbonate bond or the like, under intermediation by a spacer consisting of a (poly)oxyalkylene chain. In this manner, a functional substance-fixed liposome in which a functional substance is fixed on the liposome membrane under intermediation by the (poly)oxyalkylene chain is obtained.

50 As the functional substances to be fixed onto the liposome membrane, various substances having, or provided by introduction with, functional groups such as those mentioned above, namely, amino, hydroxyl, thiol and so on, may be enumerated. Among them, those having or provided by introduction with primary amino group are preferred. Concrete examples thereof include labelling compounds, such as pigments, dyestuffs, radioactive labelling compounds, fluorescent compounds, chemiluminescent compounds and electrode-sensitive compounds; external stimulation-responsive compounds, such as light-responsive compounds, pH-responsive compounds and heat-responsive compounds; physiological substances, such as proteins including enzymes and antibodies, sugars, lipids, glycoproteins, glycolipids and hormones; and various medicaments.


55 As the antibody, those which are reactive with the epitopes existing specifically in the cells or tissue at



the diseased site, such as polyclonal and monoclonal antibodies and partial units of them. They may be of any origin, such as human, caprine, sheep, rabbit and chicken, and of any hybridoma. As the antigen, every substance capable of being served as antigen to the antibody existing at the diseased site may be employed without limitation. For example, proteins, oligosaccharides, high molecular weight sugar, low molecular weight haptens and cholesterol may be enumerated. Here, a low molecular weight hapten should have either one of the functional groups among amino, hydroxyl and thiol in the molecule for fixation. By fixing such an antibody or antigen on the liposome, a target-directing property can be imparted to the liposome.

The functional substance-fixed liposomal vesicle according to the present invention comprises the phospholipid derivative represented by the general formula (2) as a membrane-forming component and can be obtained by reacting the reactive liposome with the functional substance. Thus, the oxycarbonylimidazole group or the substituted group thereof present on the outer face of the reactive liposome will react with the functional group in the functional substance, such as amino, hydroxyl or thiol, to build up a covalent bond of, for example, urethane bond, carbonate bond or thiocarbonate bond, whereby the functional substance is fixed firmly on the liposome surface. In the general formula (2), the symbol Y represents the residue of the functional substance bound to the vesicle.



The reaction to fix the functional substance onto the reactive liposome membrane can be realized easily in various ways including a one-step technique, which comprises subjecting the reactive liposome and the functional substance to a reaction with each other in an adequate reaction medium, such as an aqueous medium, for example, physiological saline, phosphate buffer, carbonate buffer, tris buffer, acetate buffer or borate buffer, or further, a mixture of these aqueous medium with an organic solvent, such as methanol, ethanol, acetone, acetonitrile, tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, dimethylsulfoxide and pyrrolidone, at a temperature from -10 to +120°C and, in the case of reaction with an amino group, at a temperature, preferably, from 0 to 60°C, in particular, from 0 to 40 °C, and, in the case of reaction with hydroxyl or thiol group, at a temperature, preferably, from 40 to 120 °C, for a reaction period in the range from 5 minutes to 1,000 hours, preferably from 30 minutes to 72 hours, under agitation. For fixing a protein such as antigen or antibody, it is preferable to use an aqueous reaction medium with a pH of 4 to 12, preferably 6 to 10, at a temperature of -10 to +100°C. For the fixation reaction with amino group, a temperature preferably of 0 to 60 °C, and more preferably 0 to 40 °C may be chosen. In the case of the reaction with hydroxyl or thiol group, a reaction temperature of 50 to 80 °C and a reaction duration from 30 minutes to 200 hours, preferably from 1 minute to 48 hours are preferred. Reaction conditions other than those given above are undesirable, since the stability of the liposome will become lower. These reactions are carried out preferably under agitation

A reaction sequence of the fixation of a functional substance having an amino, hydroxyl or thiol group with the liposome membrane may be explained schematically by the following reaction schemes (5a) to (5c) in which R<sup>3</sup>, OA and n are the same as those explained previously, Lip indicates the liposome and Z has the meaning as explained by these formulae, wherein H<sub>2</sub>N-Z, HO-Z and HS-Z each indicate the functional substance and -HN-Z, -O-Z and -S-Z each corresponds to Y of the general formula (2):





15.



30

The reactive vesicle according to the present invention after having been subjected to the fixation reaction can be purified, if necessary, by a known technique, such as gel filtration, ultrafiltration, dialysis, centrifugation or still sedimentation separation.

35

The reactive liposome and the functional substance-fixed liposome according to the present invention can enclose therein, namely within the aqueous phase inside the liposome cell or within the membrane itself of the liposome, various materials by a known technique, as in the conventional cellular liposomes. The material to be enclosed therein may be, for example, labelling compounds, such as pigments, dyestuffs, radioactive 40 labelling compounds, fluorescent compounds and chemiluminescent compounds; external stimulation-responsive compounds, such as light-responsive compounds, pH-responsive compounds, heat-responsive compounds and electrode-susceptible compounds; physiologically active substances, such as proteins including enzymes and antibodies, sugars, lipids, glycoproteins, glycolipids and hormones; drugs, such as medicaments; and water-soluble high polymeric materials, such as polyacrylamides, polyvinyl alcohols,  $\alpha$ -hydro- $\omega$ -hydroxy 45 polyoxyethylene and hyaluronic acid.

45

As the drugs, medicaments which are expected to maintain their concentration in blood for long period of time or to reveal a target-directing property towards a specific diseasing site or living cells may preferably be employed, such as anticancer agents, antibiotics, antiasthma agents and antiviral agents, though there is no limitation therefor. As the anticancer agent, those described in A. Kubo: "Gan Kagakuryoho" (Chemotherapy 50 of Cancer), Nankodo (1985), above all, doxorubicin, adriamycin, cisplatin, mitomycin, bleomycin, 5-fluorouracil, methotrexate, nitrogen mustard and busulfan may be mentioned. Other drugs include medicaments based on peptide, such as  $\alpha$ -,  $\beta$ - and  $\gamma$ -interferons of gene recombination type, interleukins and superoxide dismutases; antibiotics, such as sulfasan, gentamycin and streptomycin; antiprotozoals, such as meglumine antimonate; antithrombins, such as heparin, low molecular weight heparin, urokinase, thrombomodulin; immunoactivators, such 55 as muramyl peptides; and antiasthmatic agents, such as theophylline.

55

The material to be taken up can easily be enclosed within the aqueous phase in the liposome by an adequate method, for example, by using an aqueous solution containing the functional substance upon the preparation of the reactive liposome, by treating the reactive liposome or the functional substance-fixed liposome

by pH-gradient method or osmotic pressure-gradient method, etc. A material having a membrane-forming ability can be enclosed in the liposome by carrying out the liposome formation procedure using this material together with the membrane-forming components, wherein the material is drawn in the membrane of the liposome. The liposome charged with the enclosed material in this manner can then be subjected, if necessary, to purification treatment by, for example, gel filtration, ultrafiltration, dialysis, centrifugation or still sedimentation separation.

The reactive liposome and the functional substance-fixed liposome is superior in that the functional substance captured by the liposome is difficultly removed from the liposome membrane as compared with that composed of polyoxyalkylene derivative of straight chain, since two fatty acid acyl groups of  $R^1C(=O)$  and  $R^2C(=O)$  are present in the phospholipid derivative represented by the general formula (1) or (2). Therefore, the reactive liposome and the functional substance-fixed liposome according to the present invention are superior in the long term storage stability. Moreover, since the reactive liposome and the functional substance-fixed liposome according to the present invention include the (poly)oxyalkylene chains introduced therein, they are expected to have the effect of introduction of the (poly)oxyalkylene chain taught in the prior arts, such as the long term preservation of the concentration in blood, non-immunogenicity and preventive effect against the leaking out of the material enclosed in the liposome. The functional substance-fixed liposome according to the present invention has the functional substance fixed at the top end of the (poly)oxyalkylene chain, so that the function intrinsic of the functional substance can be revealed sufficiently without suffering from any hindering action of the (poly)oxyalkylene chain, resulting in a superior specificity of the reaction with a specific substance together with superior target-directing performance (accumulative ability).

The drug delivery liposome according to the present invention which is composed of the reactive liposome or of the functional substance-fixed liposome functions to carry drugs and medicaments enclosed therein to deliver them to the required site. Such delivery vesicle is difficult to be captured in reticuloendothelial organs, such as liver, so that it permits maintenance of its concentration in blood for a long period of time with lower trend to coagulation and, thus, an efficient delivery of drug can be attained. A drug delivery liposome having fixed thereon an antibody or an antigen reveals an excellent target-directing ability due to the high functioning performance of the antigen or antibody attached to the top end of the (poly)oxyalkylene chain and is utilized as drug carrier for the drug delivery system to deliver the drug or medicament to the target site at a high efficiency.

The reactive liposome and the functional substance-fixed liposome according to the present invention can be utilized for, in addition to the drug carrier, various functional liposomes and carriers therefor, such as, liposomal preparations, testing drugs, diagnostic drugs, sensors, fixed catalysts, bioreactors, elements for bioelectronics and substitutes for microcapsules, if necessary, with or without enclosing various materials mentioned above. It is also possible to utilize drug-fixed liposome, namely, a liposome containing a drug fixed thereto, as a carrier for a fixed medicament.

When a polymerizable other phospholipid derivative is employed as another membrane-forming component together with the reactive phospholipid derivative represented by the general formula (1) in producing the reactive liposomal vesicle, a polymerizable reactive liposomal vesicle can be obtained. For the polymerizable phospholipid, known ones can be employed, for example, 1,2-di(2,4-octadecadienoyl)-glycero-3-phosphocholine and those which are described in S. Shimano, J. Sunamoto and K. Inoue; "Liposomes", pp 313 - 351 (1988), issued from Nankodo. Among them, 1,2-di(2,4-octadecadienoyl)-glycero-3 phosphocholine is preferred.

The polymerizable liposome can easily be subjected to polymerization by, for example, irradiation of UV-rays,  $\gamma$ -rays and electron beams, using a redox initiator or heating in the presence of an azo-initiator, an organic peroxide or ammonium persulfate. The resulting polymerized liposome has a superior stability and, therefore, can be used in the form of aqueous suspension as such or for preparing a pulverous product by, for example, freeze drying, to serve for a stable application.

For a reactive vesicle other than liposome, a reactive fatty emulsion may be employed, which is prepared by emulsifying an oily mixture containing a phospholipid derivative represented by the general formula (1), a vegetable oil component, such as soybean oil and safflower oil, and an unmodified phospholipid component (another phospholipid component), such as soybean lecithin and yolk lecithin, in an aqueous emulsion medium together with other optionally employed additives, such as Intralipid (Trademark, Otsuka Pharmac. Co.), emulsifying assistants, stabilizers, isotonizing agents, oil-soluble drugs, such as oil-soluble medicaments and oil-soluble physiological substances. In these reactive fatty emulsions, the phospholipid derivative of the general formula (1) and other membrane-forming components are drawn up towards the interface between the oil phase of the oil droplets and the aqueous phase surrounding it and accumulate there to form a vesicle. The content of the phospholipid derivative represented by the general formula (1) in the oil mixture may preferably amount to 0.01 - 50 mole %, in particular, 0.5 - 30 mole %.

The reactive fatty emulsion can be prepared by a known method. For example, the reactive phospholipid

derivative of the general formula (1), the vegetable oil component and the unmodified phospholipid component are brought together under addition of, if necessary, other additives and the resulting mixture is then subjected to a rough emulsification on, for example, a homomixer with heating and with an addition of water, whereupon the resulting mixture is homogenized into a finished emulsion by, for example, a pressure-jet homogenizer of, such as, Manton-Gaulin type. By admixing an oil-soluble drug into the starting oil mixture for producing the fatty emulsion, a reactive fatty emulsion containing the drug in the oil droplets can be prepared.

On the so-obtained reactive fatty emulsion, various functional substances, such as those used in the reactive liposomal vesicles, can be fixed easily in the same manner, whereby a functional substance-fixed fatty emulsion of the present invention can be obtained.

The reactive fatty emulsion and the functional substance-fixed fatty emulsion can be used as drug carriers, testing drugs, diagnostic drugs, sensors and fixed catalysts.

As a reactive vesicle other than those described above, reactive micell can be employed which contains the reactive phospholipid derivative represented by the general formula (1), wherein the micell may be composed of only the phospholipid derivative of the general formula (1) or composed of a combination thereof with, for example, other micell-forming components, such as other phospholipids such as lecithin and cholesterol, oil-soluble drugs such as oil-soluble medicament, or oil-soluble physiological active substance. The reactive micell can be produced by introducing the phospholipid derivative of the general formula (1) solely or in a form of a mixture with other micell-forming component(s) into an aqueous phase in an amount sufficient to exceed above the micell forming concentration. By admixing an oil-soluble drug to the starting mixture, the reactive micell having contained therein the drug can also be produced. Also, the reactive micells of the present invention can be used for fixing thereon various functional substances in the same manner as in the reactive fatty emulsion, whereby the functional substance-fixed micell according to the present invention is obtained, which can be used, for example, as carrier for medicaments, testing drugs, diagnostic drugs, sensors and fixed catalyst, similarly to the liposome.

As detailed above, the reactive vesicle according to the present invention contains the reactive phospholipid derivative represented by the general formula (1) as a vesicle-forming component and, thus, can afford to introduce (poly)oxyalkylene chains into the vesicle and to fix on the top ends of these (poly)oxyalkylene chains a larger amount of various functional substances by a covalent bond easily and efficiently under intermediation by a spacer consisting of the (poly)oxyalkylene chain. The reactive vesicle according to the present invention is superior in the long term storage stability.

The functional substance-fixed vesicle according to the present invention contains the phospholipid derivative of the general formula (2) as the vesicle-forming component and, thus, can form a structure in which the functional substance is fixed on the surface of the vesicle under intermediation by a spacer consisting of the (poly)oxyalkylene chain, so that the functional substance fixed thereon can reveal its function sufficiently with superior long term storage stability, while maintaining the concentration of the functional substance in blood for a long period of time.

The drug delivery vesicle according to the present invention is superior in the long term stability and can maintain the concentration of the drug in blood for long time, since it comprises the afore said reactive vesicle or the functional substance-fixed vesicle. In the case of the drug delivery vesicle containing antibody or antigen fixed thereon, it permits to deliver various drugs and medicaments to the target site efficiently, due to its superior target-directing ability.



#### PREFERRED EMBODIMENT OF THE INVENTION

Below, the present invention will further be described by way of concrete examples, while these Examples should not be understood as limiting the present invention.

##### Example 1-1

1.0 g (0.3 mmol) of an  $\alpha$ -hydro- $\omega$ -carboxyl polyoxyethylene (MW = about 3,000, average addition mole number = about 65) and 68 mg (0.3 mmol) of N,N'-dicyclohexylcarbodiimide were dissolved in 10 ml of ethyl acetate and the solution was stirred at 5°C for 1 hour. Thereto was then added 10 ml of a ethyl acetate solution containing dissolved therein 217 mg (0.3 mmol) of dipalmitoyl-glycero-phosphoethanolamine and the mixture was stirred for further 6 hours and the mixture was then stood still overnight at 0 °C, where-upon the deposited matter was removed by filtration. Then, 49 mg (0.3 mmol) of N,N'-carbonyl-diimidazole were added to the filtrate and the mixture was stirred for 1 hour at room temperature, whereupon the resulting reaction mixture was poured into 100 ml of diethyl ether and the precipitate was separated by filtration to obtain the contemplated reactive phospholipid derivative of the formula (5) given below as a white powdery product (yield = 88

%). The progress of the reaction was monitored by IR spectrum (KBr method) by detecting the disappearance of the remaining amino groups in the phosphatidylethanolamine ( $\text{N}^{\text{H}_2}$ -stretching;  $3,000 \text{ cm}^{-1}$ ) and the formation of amide bonds ( $\text{C=O}$ -stretching;  $1,647 \text{ cm}^{-1}$ ) for the intermediate product, on the one hand, and detecting the disappearance of the terminal hydroxyl groups in the polyoxyethylene derivative ( $\text{OH}$ -stretching;  $3,428 \text{ cm}^{-1}$ ) and the formation of the oxycarbonylimidazole bonds ( $\text{C=O}$ -stretching;  $1,760 \text{ cm}^{-1}$ ) for the target product, on the other hand.



The observed NMR- and IR-spectra of the above reactive phospholipid derivative were as given below:

<sup>1</sup>H-NMR (CDCl<sub>3</sub>/TMS, δ : ppm, 270 MHz)

8.14 (a; s, 1H)  
 7.43 (b; t, 1H, J=1.3)  
 7.08 (c; t, 1H, J=0.8)  
 5.23 (d; m, 1H)  
 4.67 (e; t, 2H, J=2.5)  
 4.29 (f; m, 2H)  
 4.00 (g; m, 4H)  
 3.64 (h; m, ca. 255H)  
 3.06 (i; t, 2H, J=7.3)  
 2.31 (j, j'; m, 4H)  
 1.60 (k, k'; m, 4H)  
 1.26 (l, l'; m, 48H)  
 0.88 (m, m'; t, 6H, J=6.4)


### IR (KBr, cm<sup>-1</sup>)

- 1760 (oxycarbonylimidazole bond: C=O-stretch.)
- 1728 (ester: C=O-stretching)
- 1647 (amide: C=O-stretching)
- 1526 (amide: NH-deformation vibration)
- 1465 (C-H-deformation vibration)

### Example 1-2

55

The procedures of Example 1-1 were pursued with the exception that an  $\alpha$ -carboxymethyl- $\omega$ -hydroxy polyoxyethylene (average addition mole number = about 35) was used as the polyoxyalkylene derivative, whereby a reactive phospholipid derivative of the following formula (6) was obtained.



The observed NMR- and IR-spectra of the above reactive phospholipid derivative were as given below:

25       $^1\text{H-NMR}$  ( $\text{CDCl}_3/\text{TMS}$ ,  $\delta$ : ppm, 270 MHz)


- 8.14 (a; s, 1H)
- 7.43 (b; t, 1H,  $J=1.3$ )
- 7.08 (c; t, 1H,  $J=0.8$ )
- 5.23 (d; m, 1H)
- 4.67 (d; t, 2H,  $J=2.5$ )
- 4.29 (e; m, 2H)
- 4.00 (f, 7; m, 4H)
- 3.64 (g; m, ca. 140H)
- 2.31 (h, 4'; m, 4H)
- 1.60 (i, 3, 3'; m, 4H)
- 1.26 (j, 2, 2'; m, 48H)
- 0.88 (k, 1, 1'; t, 6H,  $J=6.4$ )

30      IR ( $\text{KBr}, \text{cm}^{-1}$ )



- 1760 (oxycarbonylimidazole bond: C=O-stretch.)
- 1728 (ester: C=O-stretching)
- 1647 (amide: C=O-stretching)
- 1526 (amide: NH-deformation)
- 1465 (C-H-deformation)

45      Example 1-3

The procedures of Example 1-1 were pursued with the exception that a polyoxyalkylene derivative of the following formula (7)



was used, whereby a reactive phospholipid derivative of the following formula (8) was obtained.



The observed NMR- and IR-spectra of the above reactive phospholipid derivative were as given below:

<sup>1</sup>H-NMR (CDCl<sub>3</sub>/TMS, δ : ppm, 270 MHz)

8.14 (a; s, 1H)  
 7.43 (b; t, 1H, J=1.3)  
 7.08 (c; t, 1H, J=0.8)  
 5.23 (6; m, 1H)  
 4.67 (d; t, 2H, J=2.5)  
 4.29 (8; m, 2H)  
 4.00 (5, 7; m, 4H)  
 3.60 (e,f,g; m, ca. 95H)  
 3.06 (j; t, 2H, J=7.3)  
 2.31 (4, 4'; m, 4H)  
 1.60 (3, 3'; m, 4H)  
 1.26 (2, 2'; m, 48H)  
 1.12 (h; m, ca.15H)  
 0.88 (1, 1'; t, 6H, J=6.4)


### IR (KBr, cm<sup>-1</sup>)

1760 (oxycarbonylimidazole bond: C=O-stretching)  
1728 (ester: C=O-stretching)  
1647 (amide: C=O-stretching)  
1526 (amide: NH-deformation)  
1465 (C-H-deformation)

### **Example 1-4**


1.0 g (0.3 mmol) of an  $\alpha$ -hydro- $\omega$ -carboxyl polyoxyethylene (MW = about 3,000, average addition mole number = about 65) and 68 mg (0.3 mmol) of N,N'-dicyclohexylcarbodiimide were dissolved in 10 ml of ethyl acetate and the solution was stirred at 5 °C for 1 hour. Thereto was then added 10 ml of a ethyl acetate solution containing dissolved therein 217 mg (0.3 mmol) of dipalmitoyl-glycero-phosphoethanolamine and the mixture was stirred for further 6 hours and the mixture was then stood still overnight at 0 °C, whereupon the deposited matter was removed by filtration. Then, 49 mg (0.3 mmol) of N,N'-carbonyldiimidazole were added to the filtrate and the mixture was stirred for 1 hour at room temperature, whereupon the resulting reaction mixture was poured into 100 ml of hexane and the precipitate was separated by filtration to obtain the contemplated reactive

phospholipid derivative of the formula (9) given below as a white powdery product (yield = 88 %). The progress of the reaction was monitored by IR spectrum (KBr method) by detecting the disappearance of the remaining amino groups in the phosphatidylethanolamine ( $N^+H_2$ -stretching;  $3,000\text{ cm}^{-1}$ ) and the formation of amide bonds ( $C=O$ -stretching;  $1,647\text{ cm}^{-1}$ ) for the intermediate product, on the one hand, and detecting the disappearance of the terminal hydroxyl groups in the polyoxyethylene derivative ( $OH$ -stretching;  $3,428\text{ cm}^{-1}$ ) and the formation of the oxycarbonylimidazole bonds ( $C=O$ -stretching;  $1,760\text{ cm}^{-1}$ ) for the target product, on the other hand.



#### Example 1-5

9 g (3 mmol) of an  $\alpha$ -hydro- $\omega$ -hydroxy polyoxyethylene (MW = ca. 3,000) and 1.36 g (6 mmol) of N,N'-carbonyldiimidazole were dissolved in 30 ml of chloroform and the solution was stirred at  $5^\circ\text{C}$  for 1 hour. Thereto was then added 1 ml of a chloroform solution containing dissolved therein 217 mg (0.3 mmol) of dipalmitoyl-glycero-phosphoethanolamine and the mixture was agitated for further 6 hours. The resulting reaction mixture was treated on a silica gel column (solvent: 20 % methanol/chloroform) to isolate and purify the reaction product, which was then subjected to freeze drying after the solvent was replaced by benzene, whereby the contemplated product of the reactive phospholipid derivative represented by the following formula (10) was obtained as a white powder (yield = 74 %).



The observed NMR- and IR-spectra of the above reactive phospholipid derivative were as given below:

<sup>1</sup>H-NMR (CDCl<sub>3</sub>/TMS, δ : ppm, 270 MHz)

8.14 (a; s, 1H)  
 7.43 (b; t, 1H, J=1.3)  
 7.08 (c; t, 1H, J=0.8)  
 5.23 (d; m, 1H)  
 4.67 (d; t, 2H, J=2.5)  
 4.29 (e; m, 2H)  
 4.00 (f, 7; m, 4H)  
 10 3.64 (g; m, ca. 255H)  
 2.31 (h, 4'; m, 4H)  
 1.61 (i, 3'; m, 4H)  
 1.26 (j, 2'; m, 48H)  
 0.88 (k, 1'; t, 6H, J=6.4)

15 IR (KBr, cm<sup>-1</sup>)

1760 (oxycarbonylimidazole bond: C=O-stretch.)  
 1526 (amide: NH-deformation)  
 1465 (C-H-deformation)

20 Example 2-1

40 ml of a chloroform solution containing dissolved therein 0.5 g (0.65 mmol) of dipalmitoyl-glycero-phosphocholine and 5 g (1.7 mmol) of an α-hydro-ω-hydroxy polyoxyethylene (MW = ca. 2,000, average addition mole number = about 45) were mixed with 20 ml of 1 M acetic acid buffer solution (pH 5.6) containing dissolved therein 40 units of phospholipase D (Toyo Jozo CO., Ltd.) and the mixture was stirred at 40 °C for 12 hours to react them. Then, the reaction mixture was neutralized using 0.1 N aqueous solution of sodium hydroxide and the organic phase was concentrated under a reduced pressure. The resulting reaction mixture was subjected to a chromatographic fractionation on a silica gel column (20 % methanol/chloroform) and the target product was concentrated and dissolved in a small amount of chloroform, from which the target product dipalmitoyl-glycero-phospho polyethylene glycol was obtained by re-precipitation with diethyl ether (yield = 30 %).

100 mg (0.27 mmol) of the so-obtained dipalmitoyl-glycero-phospho polyethylene glycol and 87 mg (0.54 mmol) of N,N'-carbonyldiimidazole were introduced in 10 ml of dried chloroform and the mixture was stirred at room temperature for 6 hours. The resulting reaction mixture was subjected to re-precipitation in 100 ml of diethyl ether, whereby a reactive phospholipid derivative of the following formula (11) was obtained (yield = 92 %).



The progress of the reaction was monitored by IR spectrum (KBr method) by detecting the disappearance of the terminal hydroxyl groups in the α-hydro-ω-hydroxy polyoxyethylene (OH-stretching 3,428 cm<sup>-1</sup>) and the formation of the oxycarbonylimidazole bonds (C=O-stretching; 1,760 cm<sup>-1</sup>) for the target product.

40

45

50

55



The purified product was confirmed by  $^1\text{H-NMR}$ - and IR-spectra, the results of which were as given below:

$^1\text{H-NMR}$  ( $\text{CDCl}_3/\text{TMS}$ ,  $\delta$  : ppm, 270 MHz)

- 8.14 (a; s, 1H)
- 7.43 (b; t, 1H)
- 7.08 (c; s, 1H)
- 5.23 (d; m, 1H)
- 4.67 (e; t, 2H,  $J=2.5$ )
- 3.65 (f; m, ca. 180H)
- 2.31 (g, g'; m, 4H)
- 1.60 (h, h'; m, 4H)
- 1.29 (i, i'; m, 48H)
- 0.90 (j, j'; m, 6H)



IR ( $\text{KBr}$ ,  $\text{cm}^{-1}$ )

1760 (oxycarbonylimidazole bond: C=O-stretch.)

1728 (ester: C=O-stretching)

40 Example 2-2

The procedures of Example 2-1 were pursued with the exception that the  $\alpha$ -hydro- $\omega$ -hydroxy polyoxyethylene was replaced by one having a molecular weight of about 5,000 (average addition mole number = about 115), whereby a reactive phospholipid derivative of the following formula (12) was obtained as the target product.



The purified product was confirmed by  $^1\text{H-NMR}$ - and IR-spectra, the results of which were as given below:

25  $^1\text{H-NMR}$  ( $\text{CDCl}_3/\text{TMS}$ ,  $\delta$  : ppm, 270 MHz)

- 8.14 (a; s, 1H)
- 7.43 (b; s, 1H)
- 7.08 (c; s, 1H)
- 5.23 (d; m, 1H)
- 4.67 (d; t, 2H,  $J=2.5$ )
- 4.00 (e, f; m, 4H)
- 3.65 (e; m, ca. 455H)
- 2.31 (g, h; m, 4H)
- 1.60 (i, j; m, 4H)
- 1.29 (k, l; m, 48H)
- 0.90 (m, n; m, 6H)

30 IR (KBr,  $\text{cm}^{-1}$ )

1760 (oxycarbonylimidazole bond: C=O-stretch.)

1728 (ester: C=O-stretching)

40

### Example 2-3



The procedures of Example 2-1 were pursued with the exception that the  $\alpha$ -hydro- $\omega$ -hydroxy polyoxyethylene was replaced by one having an added block-structure of

45  $(\text{oxyethylene})_p (\text{oxypropylene})_q (\text{oxyethylene})_r$ ,

in which  $p=20$ ,  $q=5$  and  $r=20$ , whereby a reactive phospholipid derivative of the following formula (13) was obtained as the target product.

50

55



( $p = 20$ ,  $q = 5$ ,  $r = 20$ ; added in blocks) . . . . . (13)

The purified product was confirmed by  $^1\text{H-NMR}$ -spectra, the results of which were as given below:

<sup>1</sup>H-NMR (CDCl<sub>3</sub>/TMS, δ : ppm, 270 MHz)

8.14 (a; s, 1H)

7.43 (b; t, 1H, J=1.3)

7.08 (c; t, 1H, J=0.8)

5.23 (6; m, 1H)

4.67 (d; t, 2H, J=2.5)

4.00 (5, 7; m, 4H)

3.60 (e,f,g,j; m, ca. 190H)

2.31 (4, 4'; m, 4H)

1.60 (3, 3'; m, 4H)

1.26 (2, 2'; m, 48H)


## 1.12 (h; m, 15H)

### Example 3-1

20 mg (26 µmol) of yolk phosphatidylcholine and 3.9 mg (10 µmol) of cholesterol were placed in an eggplant type flask together with 10 % by weight, based on the above two compounds, (2.4 mg: 0.7 µmol) of a reactive phospholipid derivative obtained in Example 1-4 and the mixture was dissolved in 2 ml of benzene, whereupon the mixture was subjected to freeze drying. Then, 1 ml of physiological saline was added thereto and, by treatment by a bath-type ultrasonication and using a vortex mixer, a mixture of multilayer liposomes was obtained. This mixture was then processed by an extruder by passing it through a series of three polycarbonate membranes of 3.0 µm, 1.0 µm and 0.2 µm successively in this order, whereby a reactive liposome as a large unilamellar vesicle was obtained. By determining the particle size of the resulting reactive liposome with a laser scattering size distribution meter [NICOMP 370HPL (Trademark) of NICOMP], an average particle size of 255 nm (with CV value of 18 %) was found.

### Example 3-2


The procedures of Example 3-1 were pursued with the exception that a reactive phospholipid derivative of the following formula (14)



was used in an amount of 5 % by weight (1.0  $\mu\text{mol}$ ), whereby a reactive liposome with an average particle size of 278 nm and a CV value of 23 % was obtained.

15 Example 3-3


The procedures of Example 3-1 were pursued with the exception that a reactive phospholipid derivative of the following formula (15)




30 was used in an amount of 30 % by weight (3.6  $\mu\text{mol}$ ), whereby a reactive liposome with an average particle size of 248 nm and a CV value of 25 % was obtained.

35 Example 3-4

The procedures of Example 3-1 were pursued with the exception that a reactive phospholipid derivative of the following formula (16)







**10** was used in an amount of 1 % by weight (0.1  $\mu\text{mol}$ ), whereby a reactive liposome with an average particle size of 250 nm and a CV value of 21 % was obtained.

### Example 3-5


<sup>15</sup> The procedures of Example 3-1 were pursued with the exception that a reactive phospholipid derivative of the following formula (17)



was used in an amount of 5 % by weight (0.6 µmol), whereby a reactive liposome with an average particle size of 250 nm and a CV value of 21 % was obtained.

**40 Example 3-6**


The procedures of Example 3-1 were pursued with the exception that a reactive phospholipid derivative of the following formula (18)



20 was used in an amount of 5 % by weight (0.1  $\mu\text{mol}$ ), whereby a reactive liposome with an average particle size of 291 nm and a CV value of 24 % was obtained.

#### Example 3-7

25 The procedures of Example 3-1 were pursued with the exception that a reactive phospholipid derivative of the following formula (19)



50 was used in an amount of 20 % by weight (4.0  $\mu\text{mol}$ ), whereby a reactive liposome with an average particle size of 221 nm and a CV value of 18 % was obtained.

#### Example 3-8

55 The procedures of Example 3-1 were pursued with the exception that the yolk phosphatidylcholine was replaced by 1,2-di(2,4-octadecadienoyl)-glycero-3-phosphocholine (DODPC), whereby a reactive liposome as a large unilamellar vesicle with an average particle size of 254 nm (CV value 23 %) which exhibited a poly-

merizability was obtained. By irradiating this liposome with a  $\gamma$ -ray of 0.75 Mrad, a polymerization of DODPC was attained. The polymerized liposome was subjected to gel filtration with Sephadex G-50 and then to freeze drying, whereby a powdery sample was obtained. This liposome powder was able to be regenerated by causing it to swell with physiological saline.

5

#### Example 4-1

20 mg (26  $\mu\text{mol}$ ) of yolk phosphatidylcholine and 3.9 mg (10  $\mu\text{mol}$ ) of cholesterol were placed in an eggplant type flask together with 10 % by weight, based on the above two compounds, (2.4 mg: 0.8  $\mu\text{mol}$ ) of a reactive phospholipid derivative obtained in Example 2-1 [ a reactive phospholipid derivative of the general formula (1-3) in which both  $R^1\text{C}(=\text{O})$  and  $R^2\text{C}(=\text{O})$  are a palmitoyl group,  $R^3$  denotes a hydrogen atom, M denotes a sodium atom, OA is an oxyethylene group and n represents a number of about 45 ] and the mixture was dissolved in 2 ml of benzene, whereupon the mixture was subjected to freeze drying. Then, 1 ml of physiological saline was added thereto and, by treatment by a bath-type ultrasonication and using a vortex mixer, a mixture of multilayer liposomes was obtained. This mixture was then processed by an extruder by passing it through a series of three polycarbonate membranes of 3.0  $\mu\text{m}$ , 1.0  $\mu\text{m}$  and 0.2  $\mu\text{m}$  successively in this order, whereby a reactive liposome as a large unilamellar vesicle was obtained. By determining the particle size of the resulting reactive liposome with a laser scattering size distribution meter [NICOMP 370HPL (Trademark) of NICOMP], an average particle size of 221 nm (with CV value of 19 %) was found.

20

#### Example 4-2

The procedures of Example 4-1 were pursued with the exception that 5 % by weight (1  $\mu\text{mol}$ ) of a reactive phospholipid derivative of the general formula (1-3) in which both  $R^1\text{C}(=\text{O})$  and  $R^2\text{C}(=\text{O})$  are a myristoyl group,  $R^3$  denotes a hydrogen atom, M denotes a sodium atom, OA is an oxyethylene group and n is a number of about 10 and 5 % by weight (0.4  $\mu\text{mol}$ ) of dimyristoyl-glycero-phospho polyethylene glycol (MW = ca. 2,000) were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size = 268 nm, CV value = 22 %).

30

#### Example 4-3

The procedures of Example 4-1 were pursued with the exception that 30 % by weight (3.5  $\mu\text{mol}$ ) of a reactive phospholipid derivative of the general formula (1-3) in which both  $R^1\text{C}(=\text{O})$  and  $R^2\text{C}(=\text{O})$  are a myristoyl group,  $R^3$  denotes a hydrogen atom, M denotes a sodium atom, OA is an oxyethylene group and n is a number of about 30 were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size = 238 nm, CV value = 22 %).

#### Example 4-4

The procedures of Example 4-1 were pursued with the exception that 1 % by weight (0.1  $\mu\text{mol}$ ) of a reactive phospholipid derivative of the general formula (1-3), in which both  $R^1\text{C}(=\text{O})$  and  $R^2\text{C}(=\text{O})$  are a stearoyl group,  $R^3$  denotes a hydrogen atom, M denotes a sodium atom and the oxyalkylene chain consists of a random addition polymeric chain composed of oxypropylene groups (average addition mole number = ca. 10) and oxyethylene groups (average addition mole number = ca. 25), and 5 % by weight (0.4  $\mu\text{mol}$ ) of dimyristoyl-glycero-phospho polyethylene glycol (MW = ca. 2,000) were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size = 239 nm, CV value = 25 %).

50

#### Example 4-5

The procedures of Example 4-1 were pursued with the exception that 5 % by weight (0.6  $\mu\text{mol}$ ) of a reactive phospholipid derivative of the general formula (1-3) in which both  $R^1\text{C}(=\text{O})$  and  $R^2\text{C}(=\text{O})$  are a stearoyl group,  $R^3$  denotes a hydrogen atom, M denotes a sodium atom and the oxyalkylene chain consists of a block-addition polymeric chain composed of a polyoxypropylene block (average addition mole number = ca. 10) and a polyoxyethylene block (average addition mole number = ca. 15) were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size = 247 nm, CV value = 19 %).

Example 4-6

The procedures of Example 4-1 were pursued with the exception that 5 % by weight (0.1  $\mu\text{mol}$ ) of a reactive phospholipid derivative of the general formula (1-3) in which both  $\text{R}^1\text{C}(=\text{O})$  and  $\text{R}^2\text{C}(=\text{O})$  are a stearoyl group, 5  $\text{R}^3$  denotes a hydrogen atom, M denotes a sodium atom and the oxyalkylene chain consists of a block-addition polymeric chain composed of a polyoxetetramethylene block (average addition mole number = 5) and a polyoxyethylene block (average addition mole number = ca. 278) were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size = 290 nm, CV value = 23 %).

10

Example 4-7

The procedures of Example 4-1 were pursued with the exception that 20 % by weight (4.2  $\mu\text{mol}$ ) of a reactive phospholipid derivative of the general formula (1-3) in which both  $\text{R}^1\text{C}(=\text{O})$  and  $\text{R}^2\text{C}(=\text{O})$  are a myristoyl group, 15  $\text{R}^3$  is methyl, M is sodium atom, OA is an oxyethylene group and n is a number of about 10 were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size = 211 nm, CV value = 19 %).

20

Example 4-8

The procedures of Example 4-1 were pursued with the exception that the yolk phosphatidylcholine was replaced by 1,2-di(2,4-octadecadienoyl)-glycero-3-phosphocholine (DODPC), whereby a reactive liposome as a large unilamellar vesicle with an average particle size of 254 nm (CV value 23 %) which exhibited a polymerizability was obtained. By irradiating this liposome with a  $\gamma$ -ray of 0.75 Mrad, a polymerization of DODPC 25 was attained. The polymerized liposome was subjected to gel filtration with Sephadex G-50 and then to freeze drying, whereby a powdery sample was obtained. This liposome powder was able to be regenerated by causing it to swell with physiological saline.

25

Example 5-1

30

0.5 ml of the reactive liposome solution (solid matter content 2.5 % by weight) obtained in Example 3-1 was stirred together with a 0.1 M phosphate buffer (pH 7.5) containing 1 mg/ml of horseradish-peroxidase (abbreviated as HRP) at 4°C for 24 hours, whereby HRP was fixed onto the reactive liposome. This was processed by a gel filtration with Sephadex G-50 to collect the liposome-containing fraction. 0.1 ml of a solution (10 mmol/l) of 1,2-phenylenediamine which is a substrate for HRP is added to the so-collected fraction and the mixture was incubated at 30 °C for 10 minutes. By adding to this 10  $\mu\text{l}$  of 0.1 N sulfuric acid, a coloration into brown was observed.

By this, it was confirmed that HRP can be fixed on the reactive liposome of Example 3-1 simply by stirring together with it.

40

Example 6-1

45

0.5 ml of the reactive liposome solution (solid matter content 2.5 % by weight) obtained in Example 4-1 was stirred together with a 0.1 M phosphate buffer (pH 7.5) containing 1 mg/ml of HRP at 4°C for 24 hours, whereby HRP was fixed on the reactive liposome. This HRP-fixed liposome was processed by a gel filtration with Sephadex G-50 to collect the liposome-containing fraction. 0.1 ml of a solution (10 mmol/l) of 1,2-phenylenediamine which is a substrate for HRP is added to the so-collected fraction and the mixture was incubated at 30 °C for 10 minutes. By adding to this 10  $\mu\text{l}$  of 0.1 N sulfuric acid, a brown coloration was observed.

50

From this, it was confirmed that HRP can be fixed on the reactive liposome of Example 4-1 simply by stirring together.

Comparative Example 1

55

The procedures of Example 3-1 were followed under the use of only the yolk phosphatidylcholine and the cholesterol in amounts of 20 mg (26  $\mu\text{mol}$ ) and 3.9 mg (10  $\mu\text{mol}$ ) respectively, whereby a large monolayer liposome with 2.5 wt. % solid was obtained. When this liposome was processed by reacting HRP thereto, purifying by gel filtration, adding thereto 0.1 ml of a solution of 1,2-phenylenediamine and incubating the mixture at 30 °C for 10 minutes, followed by addition of 10  $\mu\text{l}$  of 0.1 N sulfuric acid, in the same manner as in Example 5-1,


no coloration was found.

From this, it was shown that the liposome of this Comparative Example 1 without containing the reactive phospholipid derivative was not able to fix HRP thereon.

5 Example 7-1

40 ml of a chloroform solution containing dissolved therein 0.5 g (0.68 mmol) of dipalmitoyl-glycero-phosphocholine and 5 g (2.5 mmol) of an  $\alpha$ -hydro- $\omega$ -hydroxy polyoxyethylene (MW = ca. 2,000, average addition mole number = about 46) were mixed with 20 ml of 1 M acetic acid buffer solution (pH 5.6) containing dissolved therein 40 units of phospholipase D (Asahi Chemical Ind. CO., Ltd.) and the mixture was stirred at 40 °C for 12 hours to react them. Then, the reaction mixture was neutralized using 0.1 N aqueous solution of sodium hydroxide and the organic phase was concentrated under a reduced pressure. The resulting reaction mixture was subjected to a chromatographic fractionation on a silica gel column (20 % methanol/chloroform) and the target product was concentrated and dissolved in a small amount of chloroform, from which the target product dipalmitoyl-glycero-phospho polyethylene glycol was obtained by re-precipitation with hexane (yield = 30 %).

10 15 20 25 30 100 mg (0.37 mmol) of the so-obtained dipalmitoyl-glycero-phospho polyethylene glycol and 64 mg (0.4 mmol) of N,N'-carbonyldiimidazole were introduced in 10 ml of chloroform and the mixture was stirred at room temperature for 1 hour. The resulting reaction mixture was subjected to re-precipitation in hexane and then to ultrafiltration (fractional molecular weight = 500), followed by freeze drying, whereby a reactive phospholipid derivative of the following formula (20) was obtained.



Example 7-2

35 A phospholipid mixture containing 2 mg (2.6  $\mu$ mol) of yolk phosphatidylcholine, 1 mg (2.6  $\mu$ mol) of cholesterol and 840  $\mu$ g (6 mole % of the foregoing two) of the phospholipidderivative obtained in Example 7-1 was dissolved in 600  $\mu$ l of isopropyl ether/ chloroform (1:1 v/v). To this solution was added 300  $\mu$ l of 0.05 M borate buffer (pH 9.0). This solution was ultrasonicated for 1 minute to convert it into W/O emulsion, whereupon the emulsion was heated at 60 °C to evaporate the organic solvent off gradually. This was then passed through a polycarbonate membrane of 0.2  $\mu$ m to attain a uniform particle size, whereby a large unilamellar vesicle was obtained.

40 45 In this liposome, an anticancer agent doxorubicin (abbreviated below as DXR) was enclosed by pH-gradient method. Namely, 1 mg of DXR was dissolved in the suspension of the above-mentioned liposome and the suspension was adjusted to pH 7.8 with sodium hydroxide, whereupon the resulting suspension was incubated at 60 °C for 10 minutes. Then, the suspension was processed by a gel filtration using Sephadex G-50 to collect the liposome-containing fraction, whereby a DXR-charged liposome was obtained.

50 To the resulting liposome suspension, 500  $\mu$ g of a monoclonal antibody (abbreviated below sometimes as 34A or as monoclonal antibody 34A) against gp112 present on the surface of lung endothelial cell of mouse was added and the mixture was shaked gently at 4°C for 48 hours, whereupon the mixture was subjected to purification by a gel filtration using Sephadex G-50 to obtain a 34A-fixed DXR-charged liposome. The average particle size of this liposome was determined using a laser scattering size distribution meter [NICOMP 370HPL (Trademark) of NICOMP] to be 175 nm (CV value = 16 %).

55 After this liposome was stood still for one month at 5°C , the average particle size was determined again and found to be 179 nm with CV value of 18 %, showing thus a superior stability.

Comparative Example 2

2 mg (2.6  $\mu$ mol) of yolk phosphatidylcholine, 1 mg (2.6  $\mu$ mol) of cholesterol and 330  $\mu$ g (0.52  $\mu$ mol, 10 mole

% of the foregoing two) of  $\alpha$ -stearyl- $\omega$ -hydroxy polyoxyethylene (average addition mole number = ca. 10) were placed in an eggplant type flask and the mixture was dissolved in 2 ml of benzene, whereupon the mixture was subjected to freeze drying. Then, 1 ml of physiological saline was added thereto and, by treatment by a bath-type ultrasonication and using a vortex mixer, a mixture of multilayer liposomes was obtained. This mixture was then processed by an extruder by passing it through a series of three polycarbonate membranes of 3.0  $\mu\text{m}$ , 1.0  $\mu\text{m}$  and 0.2  $\mu\text{m}$  successively in this order, whereby a reactive liposome as a large unilamellar vesicle was obtained.

By determining the particle size of the resulting liposome in the same manner as in Example 5-1, an average particle size of 196 nm (with CV value of 11 %) was found. This was then stood still at 5 °C for one week and the average particle size was determined again, giving a value of 288 nm (CV value = 65 %). Thus, not only the average particle size but also the CV value were largely changed, showing that no stable liposome was present. From this, it is seen that the liposome containing a membrane-forming component of a polyoxyethylene derivative with a hydrophobic part of monoalkyl group exhibits inferior stability.

#### Example 8-1

##### 1) Preparation of Antibody-fixed Liposome

A phospholipid mixture containing 2 mg (2.6  $\mu\text{mol}$ ) of yolk phosphatidylcholine, 1 mg (2.6  $\mu\text{mol}$ ) of cholesterol and 840  $\mu\text{g}$  (6 mole % of the foregoing two) of the reactive phospholipid derivative obtained in Example 7-1 was dissolved in 600  $\mu\text{l}$  of isopropyl ether/chloroform (1:1 v/v) containing about 30 KBq of  $^{67}\text{Ga}$ -deferoxamine. To this solution was added 300  $\mu\text{l}$  of 0.05 M borate buffer solution (pH 9.0). This solution was ultrasonicated for 1 minute to convert it into W/O emulsion, whereupon this emulsion was heated at 60°C to evaporate the organic solvent off gradually. The resulting emulsion was passed through a polycarbonate membrane of 0.2  $\mu\text{m}$  to attain a uniform particle size, whereby a large unilamellar liposome modified with a polyethylene glycol (PEG) chain (polyoxyethylene chain) having an oxycarbonylimidazole group at its terminal end was obtained.

To the so-obtained liposome suspension, 500  $\mu\text{g}$  of a monoclonal antibody 34A and the mixture was shaked gently at 4°C for 8 hours, whereupon the mixture was purified by a gel filtration using Sephadex G-50 to obtain a liposome product modified by 34A-fixed PEG and labelled by  $^{67}\text{Ga}$  (average particle size 184 nm, CV value 15 %).

##### 2) Evaluation of Existence Ratio in Organs of Mouse after 1 Hour from Intravenous Injection of 34A-Fixed Liposome

The 34A-fixed PEG-modified liposome labelled with  $^{67}\text{Ga}$  obtained in above 1) was injected to each of three Balb/c mice (7-weeks' age, male, weight 20 - 23 g) from the tail vein at a rate of 500  $\mu\text{g}/\text{mouse}$  and the mice were slaughtered after 1 hour from the injection. By counting the  $^{67}\text{Ga}$  radioactivity in each organ, the existence ratio in the organ was calculated as the proportion to the total count upon the injection. Results are summarized in Table 1 below.

##### Comparative Example 3-1

Using a phospholipid mixture containing 2 mg (2.6  $\mu\text{mol}$ ) of yolk phosphatidylcholine, 1 mg (2.6  $\mu\text{mol}$ ) of cholesterol and 840  $\mu\text{g}$  (6 mole % of the foregoing two) of the reactive phospholipid derivative obtained in Example 7-1, the procedures of Example 8-1 were followed until the stage of passing through the polycarbonate membrane, whereby a PEG-modified liposome labelled with  $^{67}\text{Ga}$  was obtained (average particle size 188 nm, CV value 15 %). Using this liposome, the existence ratio of the radioactivity in organs of mouse was observed. Results are summarized also in Table 1 below.

##### Comparative Example 3-2

A phospholipid mixture containing 2 mg (2.6  $\mu\text{mol}$ ) of yolk phosphatidylcholine, 1 mg (2.6  $\mu\text{mol}$ ) of cholesterol and 230  $\mu\text{g}$  (6 mole % of the foregoing two) of N-glutaryl-distearylethanamine was dissolved in 600  $\mu\text{l}$  of isopropylether/chloroform (1:1 v/v) containing about 30 KBq of  $^{67}\text{Ga}$ -deferoxamine. To this solution was added 300  $\mu\text{l}$  of a 10 mM 2-(N-morpholino)-ethanesulfonate buffer solution (pH 5.5) containing 150 mM of sodium chloride. This solution was ultrasonicated for 1 minute to convert it into W/O emulsion, whereupon this emulsion was heated at 60°C to evaporate the organic solvent off gradually. The resulting emulsion was passed

through a polycarbonate membrane of 0.2 µm to attain a uniform particle size, whereby a  $^{67}\text{Ga}$ -labelled liposome was obtained.

To the so-obtained liposome suspension, 58 µl of 0.25 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride and 58 µl of 0.1 M N-hydroxysuccinimide were added and the mixture was shaked gently at room temperature for 10 minutes, whereby a liposome comprising a polyoxyalkylene (PEG) chain having at its terminal end an active ester group was obtained. This was then adjusted using 50 µl of 1 M phosphate buffer solution (pH 7.5) and 1 N aqueous sodium hydroxide to pH 7.5, whereto 500 µg of the monoclonal antibody 34A against gp112 existing on the surface of lung endothelial cell of mouse and the mixture was shaked gently at 4°C for 8 hours and subjected to purification by a gel filtration using Sephadex G-50, whereby a 34A-fixed liposome labelled with  $^{67}\text{Ga}$  was obtained (average particle size 188 nm, CV value 23 %). Using this liposome, the existence ratio in organs of mouse was observed in the same manner as in Example 8-1. The results are summarized in Table 1 below.

#### Comparative Example 3-3

Using a phospholipid mixture containing 2 mg (2.6 µmol) of yolk phosphatidylcholine and 1 mg (2.6 µmol) of cholesterol only, the procedures of Example 8-1 were followed until the stage of passing through the polycarbonate membrane, whereby a  $^{67}\text{Ga}$ -labelled liposome was obtained. Using this liposome, the existence ratio of the liposome in organs of mouse was observed as in Comparative Example 3-2. Results are summarized also in Table 1 below.

Table 1


Organ	Example 8-1	Compar. Examp. 3-1	Compar. Examp. 3-2	Compar. Examp. 3-3
Lung	52.70 ± 1.7	0.7 ± 0.11	16.03 ± 0.1	1.15 ± 0.01
Blood	5.00 ± 0.5	59.00 ± 10.0	5.9 ± 0.5	24.8 ± 0.7
Liver	16.10 ± 0.7	17.00 ± 0.9	48.1 ± 2.8	40.4 ± 1.6
Kidney	1.76 ± 0.2	2.80 ± 0.3	1 ± 0.2	3.9 ± 0.05
Spleen	3.90 ± 0.3	4.73 ± 0.27	7.26 ± 0.7	2 ± 0.6
Heart	0.57 ± 0.07	1.20 ± 0.10	0 ± 0	0.5 ± 0.1

Note: The values are each an average of 3 mice ± standard error

From the above, it was shown that the liposome product of Example 8-1 having fixed thereon antibody 34A reactive specifically to lung endothelial cell had a superior accumurability (target-directing ability) in lung as compared with the PEG-modified liposome product of Comparative Example 3-1, the liposome product of Comparative Example 3-2 having fixed thereon 34A without PEG chain and the conventional liposome product of Comparative Example 3-3. The liposome product of Example 8-1 showed a lower existence ratio in blood than that of Comparative Examples of 3-1 etc., which may be due to the accumulation in lung and do not indicate that the concentration is not maintained in blood.

#### Claims

1. A phospholipid derivative represented by the general formula (1):



10 in which

$R^1C(=O)$  and  $R^2C(=O)$  are independently selected from aliphatic acyl groups having 3 - 30 carbon atoms;  $R^3$  denotes a hydrogen atom or a methyl group.

OA represents an oxyalkylene group having 2-4


$\text{CA}_n$  represents an oxyalkylene group having 2-4 carbon atoms;  $n$  indicates the average addition mole number of added oxyethylene groups.

*n* indicates the average addition mole number of added oxyalkylene groups and is a positive number of 1-1,000, with the proviso that when *n* is 2 or more the oxyalkylene groups are independently selected from one another and may be added randomly or in a block;


p is 0 or 1;

**X** represents the group

20



36



wherein q is an integer of 0 to 4 and r is an integer of 1 to 4; and M denotes a hydrogen atom or an alkali metal atom.

30

**2. A phospholipid derivative as claimed in claim 1,  
wherein X is**

35



40

**3. A phospholipid derivative as claimed in claim 1,  
wherein X is**

45




**4. A phospholipid derivative as claimed in claim 1,  
wherein  $n = \Omega$**

50

#### **5. Use of a phospholipid derivative according to any of claims 1 to 4 as a vesicle-forming agent**

**6. A vesicle comprising a phospholipid derivative as claimed in any of claims 1 to 1**

7. A functional substance-fixed vesicle comprising a phospholipid derivative represented by the general formula (2):



10 in which  
 R<sup>1</sup>C(=O), R<sup>2</sup>C(=O), R<sup>3</sup>, OA, n, p, X, q, r and M are as defined in claim 1, and Y is a residue of a functional substance.

- 15 8. A vesicle according to claim 7, wherein the functional substance comprises a functional group selected from amino, hydroxyl and thiol groups.
- 9. A vesicle as claimed in claim 7 or claim 8, wherein the functional substance is an antibody or an antigen.
- 10. A vesicle as claimed in any of claims 6 to 9, wherein the vesicle is a liposome.
- 20 11. A vesicle as claimed in any of claims 6 to 10, which contains a drug within the vesicle.
- 12. A drug delivery system for transporting a drug to a target site comprising a vesicle according to claim 11.

25

30

35

40

45

50

55



## EUROPEAN SEARCH REPORT

Application Number  
EP 94 30 9061

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)						
D,A	WO-A-90 04384 (ROYAL FREE HOSPITAL SCHOOL OF MEDICINE) * the whole document *	1-6	C07F9/6506 A61K9/127 C08G65/32 A61K47/48 A61K47/30						
D,A	EP-A-0 526 700 (MITSUBISHI KASEI CORPORATION) * the whole document *	1-6							
D,A	WO-A-91 16040 (TAKEDA CHEMICAL INDUSTRIES LTD.) * the whole document *	1-6							
A	US-A-5 190 822 (NAOYUKI NISHIKAWA) * the whole document *	1-6							
A	JOURNAL OF LIPOSOME RESEARCH, vol.2, no.3, 1992, NEW YORK US pages 321 - 334 A. L. KLIBANOV 'Long-circulating liposomes: development and perspectives' * page 330 - page 331; figure B *	7-12							
P,A	WO-A-94 22429 (LIPOSOME TECHNOLOGY) * the whole document *	1-12	C07F A61K C08G						
P,A	DATABASE WPI Section Ch, Week 9423, Derwent Publications Ltd., London, GB; AN 94-188081 & JP-A-6 126 152 (NIPPON OILS & FATS CO. LTD.) 10 May 1994 * abstract *	1-6							
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>3 March 1995</td> <td>Beslier, L</td> </tr> </table> <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone      Y : particularly relevant if combined with another document of the same category      A : technological background      O : non-written disclosure      P : intermediate document</p> <p>T : theory or principle underlying the invention      E : earlier patent document, but published on, or after the filing date      D : document cited in the application      L : document cited for other reasons      &amp; : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	3 March 1995	Beslier, L
Place of search	Date of completion of the search	Examiner							
THE HAGUE	3 March 1995	Beslier, L							

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**